Ron M Kagan

US Patent:

20050059035, Mar 17, 2005

Filed:

Feb 9, 2004

Appl. No.:

10/775650

Inventors:

Doug Huang - Irvine CA, US
Feras Hantash - Dana Point CA, US
Ron Kagan - Mission Viejo CA, US

International Classification:

C12Q001/68
C07H021/04
C12P019/34

US Classification:

435006000, 435091200, 536023200

Abstract:

The present invention provides nucleic acid primers for amplifying DNA sequences of normal and mutant cystic fibrosis (CF) genes. These primers enable the construction of assays that use the amplified CF genes to detect of the presence of normal or mutant CF sequence, thereby enabling the detection of the genotype of cystic fibrosis in a biological sample. Various pairs of primers suitable for amplifying different CFTR gene segments are provided which are suitable for use in a multiplex amplification format.

US Patent:

20030130801, Jul 10, 2003

Filed:

Jan 8, 2002

Appl. No.:

10/042774

Inventors:

Ron Kagan - Mission Viejo CA, US

International Classification:

G06F007/00

US Classification:

702/020000

Abstract:

A control method, apparatus, and system to actively assure the quality of a biological sample through genetic or nucleic acid sequence screening. The genetic information from the biological sample is sequenced and associated with patient information, such as patient name or other patient identifier. The genetic sequence is then compared with other entries in a sequence database to determine the closest matches within the database, and further compared with a confidence threshold. A report may then be generated indicating whether the closest matches within the confidence threshold match the patient information. The quality assurance integrity of the biological sample can be determined when the patient information of the biological sample matches previous samples from the same patient.